Anti-CD37 antibody is currently being evaluated in adult B-cell malignancies (NHL, CLL, MM, ALL) as a drug conjugate with the maytansine derivative DM1 (20). This evidence concerns the gene CD37 and non-Hodgkin lymphoma.